Image of Navid Madani
Navid Madani, PhD
Research Associate in Microbiology, Dana-Farber Cancer Institute

Navid Madani, PhD, is a Senior Scientist in Dana-Farber Cancer Institute's Department of Cancer Immunology and Virology, with appointments at Harvard Medical School in the Departments of Microbiology and Global Health and Social Medicine. Currently, she is the principal investigator on a study that is optimizing the application of a CD4-mimetic small-molecule inhibitor of HIV-1 infection as topical microbicides. Madani has applied a deep knowledge of research and scientific-based approaches to public health projects in the areas of cancer and infectious diseases in the MENA region. The SHE Center was born out of her past decade of work in the region — bringing together crucial stakeholders within key populations.

Madani’s research emphasizes HIV/AIDS, drug discovery, and the development of a woman-controlled microbicide to halt HIV transmission. She uses a multidisciplinary approach to find preventive measures to inhibit HIV-1 transmission. Her studies have led to the biochemical characterization of two classes of small molecules that bind HIV-1 gp120 and inhibit HIV-1 entry.

Structural and Functional Characterization of Indane-Core CD4-Mimetic Compounds Substituted with Heterocyclic Amines.
Authors: Authors: Chaplain C, Fritschi CJ, Anang S, Gong Z, Richard J, Bourassa C, Liang S, Mohammadi M, Park J, Finzi A, Madani N, Sodroski JG, Abrams CF, Hendrickson WA, Smith AB.
ACS Med Chem Lett
View full abstract on Pubmed
Be the voice for scientists in Iran.
Authors: Authors: Madani N.
Science
View full abstract on Pubmed
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
Authors: Authors: Anang S, Richard J, Bourassa C, Goyette G, Chiu TJ, Chen HC, Smith AB, Madani N, Finzi A, Sodroski J.
J Virol
View full abstract on Pubmed
Does COVID-19 Escalate Aging Process? A Possible Concern.
Authors: Authors: Tayeri K, Asadollahi K, Madani N, Haghjooy Javanmard S.
Adv Biomed Res
View full abstract on Pubmed
Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics.
Authors: Authors: Fritschi CJ, Liang S, Mohammadi M, Anang S, Moraca F, Chen J, Madani N, Sodroski JG, Abrams CF, Hendrickson WA, Smith AB.
ACS Med Chem Lett
View full abstract on Pubmed
Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges.
Authors: Authors: Aghila Rani KG, Hamad MA, Zaher DM, Sieburth SM, Madani N, Al-Tel TH.
Expert Opin Drug Discov
View full abstract on Pubmed
COVID-19 response in the Middle East and north Africa: challenges and paths forward.
Authors: Authors: Karamouzian M, Madani N.
Lancet Glob Health
View full abstract on Pubmed
The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site.
Authors: Authors: Prévost J, Tolbert WD, Medjahed H, Sherburn RT, Madani N, Zoubchenok D, Gendron-Lepage G, Gaffney AE, Grenier MC, Kirk S, Vergara N, Han C, Mann BT, Chénine AL, Ahmed A, Chaiken I, Kirchhoff F, Hahn BH, Haim H, Abrams CF, Smith AB, Sodroski J, Pazgier M, Finzi A.
mBio
View full abstract on Pubmed
Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
Authors: Authors: Zou S, Zhang S, Gaffney A, Ding H, Lu M, Grover JR, Farrell M, Nguyen HT, Zhao C, Anang S, Zhao M, Mohammadi M, Blanchard SC, Abrams C, Madani N, Mothes W, Kappes JC, Smith AB, Sodroski J.
J Virol
View full abstract on Pubmed
Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
Authors: Authors: Joshi VR, Newman RM, Pack ML, Power KA, Munro JB, Okawa K, Madani N, Sodroski JG, Schmidt AG, Allen TM.
PLoS Pathog
View full abstract on Pubmed